ABSTRACT Introduction As of May 2023, 19 and 18 biosimilars have been approved for the
treatment of rheumatoid arthritis (RA) by the European Medicines Agency (EMA) and United …

Biologics are effective, though costly, medications for the treatment of rheumatoid arthritis
(RA). Biosimilars are medications that have no clinically meaningful differences when …

Prescription drug prices continue to rise unabated in the United States, largely due to a
system that allows brand-name drug makers to charge whatever the market will bear. Some …

Since 2015 more than 30 biosimilars have been approved by the FDA, with over 20
launched. This new era of biosimilar competition has stimulated renewed technology …

Introduction Biosimilars are gaining popularity in Latin America (LA). The biosimilars market
is expected to grow rapidly over the next decade as a cost-effective alternative to expensive …

To produce innovative biopharmaceuticals, highly flexible, adaptable, robust, and affordable
bioprocess platforms for bioreactors are essential. In this article, we describe the …

Access to affordable healthcare–including medicines, is considered to be an integral
element of the right to health. Individual countries are expected to develop legislation and …

Biological medicines have significantly altered treatment for many patients with chronic
diseases such as cancers, autoimmune diseases, and diabetes. However, the high cost of …

In the last decade, the expiration of patents protecting therapeutic monoclonal antibodies
opened an opportunity for the development and approval of biosimilar versions of these …

For assessment of biosimilar drug products, if there are multiple-reference products (eg, a
US-licensed product and an EU-approved product), a biosimilar bridging study with a 3-way …